![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Geron grants Janssen Biotech global rights to imetelstat; deal terminated
Executive Summary
Just a couple weeks after the FDA removed a clinical hold on its modified oligonucleotide imetelstat, cancer-focused Geron Corp. licensed Janssen Biotech Inc. exclusive worldwide rights to develop and commercialize the telomerase inhibitor (GRN163L) for oncology indications, including myeloid malignancies, and all other human therapeutic uses. Janssen will pay $35mm up front initially, up to $900mm in development, regulatory, and commercial milestones, plus sales royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice